Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data

被引：576
作者：
van der Velden, V. H. J.
Cazzaniga, G.
Schrauder, A.
Hancock, J.
Bader, P.
Panzer-Grumayer, E. R.
Flohr, T.
Sutton, R.
Cave, H.
Madsen, H. O.
Cayuela, J. M.
Trka, J.
Eckert, C.
Foroni, L.
zur Stadt, U.
Beldjord, K.
Raff, T.
van der Schoot, C. E.
van Dongen, J. J. M.
机构：
[1] Erasmus MC, Dept Immunol, NL-3015 GE Rotterdam, Netherlands
[2] Univ Milan, Ctr Ric Tettamanti, Monza, Italy
[3] Univ Hosp Schleswig Holstein, Dept Pediat, Kiel, Germany
[4] Univ Bristol, Dept Cellular & Mol Med, Bristol BS8 1TH, Avon, England
[5] Klinikum Johann Wolfgang Goethe Univ, Frankfurt, Germany
[6] Childrens Canc Res Inst, Vienna, Austria
[7] St Anna Childrens Hosp, Vienna, Austria
[8] Heidelberg Univ, Inst Human Genet, Heidelberg, Germany
[9] Univ NSW, Childrens Canc Inst Australia Med Res, Sydney, NSW, Australia
[10] Hop Robert Debre, Biochim Genet Lab, F-75019 Paris, France
[11] Rigshosp, Dept Clin Immunol, DK-2100 Copenhagen, Denmark
[12] Hop St Louis, Cent Hematol Lab, Paris, France
[13] Charles Univ Prague, Dept Paediat Haematol Oncol, Sch Med 2, Prague, Czech Republic
[14] Charite Med Ctr CVK, Dept Paediat Oncol & Hematol, Berlin, Germany
[15] UCL Royal Free & Univ Coll, Sch Med, Dept Acad Haematol, London, England
[16] Univ Med Ctr Hamburg Eppendorf, Dept Pediat Hematol & Oncol, Hamburg, Germany
[17] Hop Necker Enfants Malad, Hematol Lab, Paris, France
[18] Univ Klinikum Schleswig Holstein, Med Klin 2, Kiel, Germany
[19] Sanquin, Dept Expt Immunohematol, Amsterdam, Netherlands
来源：
LEUKEMIA | 2007年 / 21卷 / 04期
关键词：
MRD; ALL; Ig/; TCR; RQ-PCR; guidelines;
D O I：
10.1038/sj.leu.2404586
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Most modern treatment protocols for acute lymphoblastic leukaemia (ALL) include the analysis of minimal residual disease (MRD). To ensure comparable MRD results between different MRD-polymerase chain reaction (PCR) laboratories, standardization and quality control are essential. The European Study Group on MRD detection in ALL (ESG-MRD-ALL), consisting of 30 MRD-PCR laboratories worldwide, has developed guidelines for the interpretation of real-time quantitative PCR-based MRD data. The application of these guidelines ensures identical interpretation of MRD data between different laboratories of the same MRD-based clinical protocol. Furthermore, the ESG-MRD-ALL guidelines will facilitate the comparison of MRD data obtained in different treatment protocols, including those with new drugs.
引用
收藏
页码：604 / 611
页数：8
相关论文
共 23 条
[11]   Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome [J].
Nyvold, C ;
Madsen, HO ;
Ryder, LP ;
Seyfarth, J ;
Svejgaard, A ;
Clausen, N ;
Wesenberg, F ;
Jonsson, OG ;
Forestier, E ;
Schmiegelow, K .
BLOOD, 2002, 99 (04) :1253-1258
[12]   Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia [J].
Panzer-Grümayer, ER ;
Schneider, M ;
Panzer, S ;
Fasching, K ;
Gadner, H .
BLOOD, 2000, 95 (03) :790-794
[13]   New definition of remission in childhood acute lymphoblastic leukemia [J].
Pui, CH ;
Campana, D .
LEUKEMIA, 2000, 14 (05) :783-785
[14]  
SCHRAPPE M, 2002, HEMATOL J, V3, P127
[15]   Cross-lineage T cell receptor gene rearrangements occur in more than ninety percent of childhood precursor-B acute lymphoblastic leukemias:: alternative PCR targets for detection of minimal residual disease [J].
Szczepanski, T ;
Beishuizen, A ;
Pongers-Willemse, MJ ;
Hählen, K ;
Van Wering, ER ;
Wijkhuijs, AJM ;
Tibbe, GJM ;
De Bruijn, MAC ;
Van Dongen, JJM .
LEUKEMIA, 1999, 13 (02) :196-205
[16]   Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects [J].
van der Velden, VHJ ;
Hochhaus, A ;
Cazzaniga, G ;
Szczepanski, T ;
Gabert, J ;
van Dongen, JJM .
LEUKEMIA, 2003, 17 (06) :1013-1034
[17]   Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR [J].
van der Velden, VHJ ;
Willemse, MJ ;
van der Schoot, CE ;
Hählen, K ;
van Wering, ER ;
van Dongen, JJM .
LEUKEMIA, 2002, 16 (05) :928-936
[18]   Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood [J].
van Dongen, JJM ;
Seriu, T ;
Panzer-Grümayer, ER ;
Biondi, A ;
Pongers-Willemse, MJ ;
Corral, L ;
Stolz, F ;
Schrappe, M ;
Masera, G ;
Kamps, WA ;
Gadner, H ;
van Wering, ER ;
Ludwig, WD ;
Basso, G ;
de Bruijn, MAC ;
Cazzaniga, G ;
Hettinger, A ;
van der Does-van den Berg, A ;
Hop, WCJ ;
Riehm, H ;
Bartram, CR .
LANCET, 1998, 352 (9142) :1731-1738
[19]   Regeneration pattern of precursor-B-cells in bone marrow of acute lymphoblastic leukemia patients depends on the type of preceding chemotherapy [J].
van Lochem, EG ;
Wiegers, YM ;
van den Beemd, R ;
Hählen, K ;
van Dongen, JJM ;
Hooijkaas, H .
LEUKEMIA, 2000, 14 (04) :688-695
[20]   Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease [J].
van Wering, ER ;
Van der Linden-Schrever, BEM ;
Szczepanski, T ;
Willemse, MJ ;
Baars, EA ;
Van Wijngaarde-Schmitz, HM ;
Kamps, WA ;
Van Dongen, JJM .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 110 (01) :139-146
123